Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gadflies never become beautiful, iridescent butterflies (it's in the DNA).
They're programmed to irritate.
[quote]So if U were a BP Ceo …. Would U buy AUPH knowing that at least the data KZR has on the refractory patients was pretty impressive [/quote]Yes, I would buy it. That would give the acquiring company years of time to fully penetrate the market, and the fear of a competitor coming online (maybe!) with marginal advantages (maybe!), very little reason to worry.
It seems that to get the medical community to accept a new drug is like turning an ocean liner quickly. It's not easy. A multi-year head-start would be very hard to overcome, unless KZR demonstrates a huge advantage in efficacy and convenience and side effects, which the trial just published does not indicate.
You seem to be suffering from a recurring nightmare! Relax, don't worry, stay calm, take a nap... everything will work out.
OK, so we have (again!) a fine example of poisonous "analysis" by a Pluristem "investor" (LOL!)
I think you're quite right: either the Tnuva agreement or the clinical study could give us a VERY substantial PPS boost.
"Cautious optimism" is a reasonable stance (as with any small pre-product biotech), but my sense is (and has been) that Pluristem is smack in the middle of one of the most important avant-guard areas of medical advance, and the likelihood of monetizing their accumulated technical know-how and patent base is reasonably high.
Very interesting!
BR (aka "gadfly"), sarcasm is a powerful tool, but has to be used properly to be effective.
My "insightful" comment was in response to "WhataBomber" who insinuated that I was unaware of this obvious potential (of acquisition).
You're too eager, thus the misfire is not surprising.